Venashinjung 5 mg (Solifenacin Succinate)

Adult dosage

The usual recommended dose for adults (including elderly patients) is 5mg once daily. If necessary, the dose may be increased to a maximum of 10mg once daily. This drug may be taken with or without food and should be swallowed whole with water. 1. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Use with caution in patients with severe renal impairment (creatinine clearance≤30ml/min), and do not exceed 5mg once daily. 2. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. Use with caution in patients with moderate hepatic impairment (Child-Pugh class B), and do not exceed 5mg once daily. 3. Patients receiving potent cytochrome P450 3A4 (CYP3A4) inhibitors For patients receiving ketoconazole or other potent CYP3A4 inhibitors (e.g., ritonavir, nelfinavir, itraconazole), limit the maximum daily dose to 5mg.

This medication should not be used in patients with urinary retention symptoms. Patients with severe gastrointestinal disorders, myasthenia gravis, or angle-closure glaucoma should also avoid using this medication. It is contraindicated for individuals allergic to this medication or its ingredients, patients undergoing dialysis, and those with severe liver or kidney function impairment. Patients with certain genetic metabolic disorders should also refrain from using this medication. In patients with severe urinary outlet obstruction or gastrointestinal obstruction, and those with moderate to severe renal or liver function impairment, this medication should be used with caution. Common side effects include dry mouth, constipation, blurred vision, urinary retention, dry eyes, dizziness, depression, nausea, indigestion, upper abdominal pain, vomiting, urinary tract infection, influenza, pharyngitis, lower limb edema, fatigue, cough, hypertension, difficulty in urination, decreased urine flow, bladder outlet obstruction, cystitis, rhinitis, vomiting, gastroesophageal reflux disease, intestinal obstruction, peripheral edema, headache, hallucinations, drowsiness, delirium, kidney disorders, itching, rash, angioedema, erythema multiforme, exfoliative dermatitis, and serious allergic reactions may occur, particularly with high-dose administration, necessitating caution. Patients should be careful while driving or operating machinery as this medication may cause drowsiness or fatigue. Patients with QT prolongation syndrome or hyperkalemia are at risk for cardiac arrhythmias and should be cautious. If serious allergic reactions such as angioedema or anaphylaxis occur, the medication should be discontinued immediately, and appropriate treatment should be sought. This medication is metabolized by specific enzymes; therefore, dosage adjustments are necessary when taken with strong CYP3A4 inhibitors. Pregnant women and nursing mothers should be cautious when taking this medication, and its safety in children has not been established, so it is advisable not to use it in pediatric patients. In the case of overdose, appropriate detoxification treatment is required, and professional treatment should be sought for serious symptoms.

• dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• fecal impaction
• colonic obstruction
• intestinal obstruction
• angioedema
• nausea

This medication can be sensitive to air and moisture, so it must be stored in a tightly sealed container. Avoid extremely hot or cold places, and it is best to store it at room temperature between 1 to 30 degrees Celsius.

Appearance

Bright yellow round film-coated tablets

Package unit

100 tablets (10 tablets/PTP x 10)